Effect of sodium phenylbutyrate/taurursodiol on tracheostomy/ventilation-free survival and hospitalisation in amyotrophic lateral sclerosis: long-term results from the CENTAUR trial

• DOI: 10.1136/jnnp-2022-329024
• Publication Date: 2022-05-23T17:35:26Z
• Authors: Sabrina Paganoni; Suzanne Hendrix; Samuel P Dickson; Newman Knowlton; James D Berry; Michael A Elliott; Samuel Maiser; Chafic Karam; James B Caress; Margaret Ayo Owegi; Adam Quick; James Wymer; Stephen A Goutman; Daragh Heitzman; Terry D Heiman-Pa...; Carlayne Jackson; Colin Quinn; Jeffrey D Rothstein; Edward J Kasarskis; Jonathan Katz; Liberty Jenkins; Shafeeq S Ladha; Timothy M Miller; Stephen N Scelsa; Tuan H Vu; Christina Fournier; Kristin M Johnson; Andrea Swenson; Namita Goyal; Gary L Pattee; Suma Babu; Marianne Chase; Derek Dagostino; Meghan Hall; Gale Kittle; Mathew Eydinov; Joseph Ostrow; Lindsay Pothier; Rebecca Randall; Jeremy M Shefner; Alexander V Sherman; Eric Tustison; Prasha Vigneswaran; Hong Yu; Joshua Cohen; Justin Klee; Rudolph Tanzi; Walter Gilbert; Patrick Yeramian; Merit Cudkowicz
• Keywords: Phenylbutyrate

Coformulated sodium phenylbutyrate/taurursodiol (PB/TURSO) was shown to prolong survival and slow functional decline in amyotrophic lateral sclerosis (ALS).